Randomized Placebo-Controlled Trial of Reloxaliase in Enteric Hyperoxaluria.

Reloxaliase in Enteric HyperoxaluriaPatients with enteric hyperoxaluria received reloxaliase or placebo with food for 4 weeks. Urinary oxalate excretion decreased from 83.2 to 67.4 mg/24 hr during weeks 1 to 4 with reloxaliase compared with 84.2 to 78.1 mg/24 hr with placebo (P=0.004). Adverse events occurred for 69% of reloxaliase-treated patients versus 53% of those receiving placebo.